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Introduction
Osteoarthritis (OA) is a chronic disease of the joints 
characterized by progressive destruction of articular 
cartilage resulting in painful, limited joint movement. In 
the European Union over 39 million people exhibit 
symptoms of OA, a number anticipated to double in the 
next decade, creating an imperative for the timely develop-
ment of eﬀ  ective treatments for the disease [1]. Current 
clinical therapies such as pharmaceutical inter  ventions, 
bone marrow stimulation techniques or micro  fracture do 
not result in regeneration of healthy cartilage tissue [2,3], 
but focus on the short-term relief of OA symptoms. When 
pharmaceutical intervention fails, clinicians regularly 
revert to invasive and permanent solutions.
Th  e ﬁ   rst widely accepted regenerative treatment for 
cartilage repair was autologous chondrocyte transplan-
tation. Despite its initial therapeutic promise, chondro-
cyte transplantation has associated complications, such 
as donor site morbidity, repair cell de-diﬀ  erentiation with 
expansion in vitro and restricted cellular life span upon 
implantation [4]. Immature progenitor cells with the 
potential to develop into mature tissues in response to 
appropriate cues have therefore become a primary focus 
of cartilage repair strategies as an alternative to 
chondrocyte-based methods [5].
Th  e application of chondroprogenitors, cells that are 
speciﬁ   cally pre-disposed to diﬀ   erentiate into mature 
chondrocytes, to repair articular lesions and subsequently 
inhibit the onset of OA is a current focus of research 
eﬀ   orts. As the mature articular joint develops from 
embryonic mesodermal precursors that diﬀ  erentiate into 
chondroprogenitors and ultimately into mature adult 
chondrocytes or synoviocytes, it is hypothesized that 
progenitors retained in these adult articular tissues 
provide a potential reservoir of chondroprogenitors.
Abstract
Mesenchymal progenitor cells, a multipotent adult stem cell population, have the ability to diff  erentiate into cells 
of connective tissue lineages, including fat, cartilage, bone and muscle, and therefore generate a great deal of 
interest for their potential use in regenerative medicine. During development, endochondral bone is formed from a 
template of cartilage that transforms into bone; however, mature articular cartilage remains in the articulating joints, 
where its principal role is reducing friction and dispersing mechanical load. Articular cartilage is prone to damage 
from sports injuries or ageing, which regularly progresses to more serious joint disorders, such as osteoarthritis. 
Osteoarthritis is a degenerative joint disease characterized by the thinning and eventual wearing of articular cartilage, 
and aff  ects millions of people worldwide. Due to low chondrocyte motility and proliferative rates, and complicated 
by the absence of blood vessels, cartilage has a limited ability to self-repair. Current pharmaceutical and surgical 
interventions fail to generate repair tissue with the mechanical and cellular properties of native host cartilage. The 
long-term success of cartilage repair will therefore depend on regenerative methodologies resulting in the restoration 
of articular cartilage that closely duplicates the native tissue. For cell-based therapies, the optimal cell source must be 
readily accessible with easily isolated, abundant cells capable of collagen type II and sulfated proteoglycan production 
in appropriate proportions. Although a cell source with these therapeutic properties remains elusive, mesenchymal 
chondroprogenitors retain their expansion capacity with the promise of reproducing the structural or biomechanical 
properties of healthy articular cartilage. As current knowledge regarding chondroprogenitors is relatively limited, this 
review will focus on their origin and therapeutic application.
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Th  e development of the embryonic appendicular skele-
ton, whereby undiﬀ  erentiated limb mesenchyme matures 
into a cartilaginous precursor and subsequently into 
bone, is dependent upon precursor exposure to speciﬁ  c 
combinations of morphogens and mechanical stimuli. 
Presumably a residual chondroprogenitor in the adult has 
been similarly primed and, when further stimulated, will 
respond by undergoing chondrogenic diﬀ  erentiation. Of 
critical importance during this developmental process 
are the transforming growth factor (TGF)-β, ﬁ  broblast 
growth factor (FGF), Wnt and Notch signaling pathways.
In embryonic limb development, FGF-4 stimulates Sonic 
hedgehog (Shh) expression in a positive feedback loop that 
coordinates proximal-distal and anterior-posterior 
patterning of the cartilaginous anlagen, as was historically 
demonstrated in an avian model [6]. Shh, in turn, initiates 
a cascade of stimulatory molecules such as those of the 
TGF-β superfamily, thereby inducing mesenchymal 
diﬀ   er  entiation into chondrocytes, as was originally 
demon  strated in murine limb mesenchyme [7]. Similarly, 
FGF-18 promotes cartilage formation in murine limb 
progenitor in vitro micromass cultures [8]. Th  is  eﬀ  ect is 
currently under clinical investigation for cartilage repair 
[9]. Th  is phase I safety study assesses the ability of 
FGF-18 to stimulate chondrocyte development leading to 
the repair and regeneration of articular cartilage in 
patients undergoing knee replacement surgery. As FGF 
receptor isoform expression is highly regulated during 
each stage of embryonic human limb chondrogenesis 
[10], conserved FGF receptor expression patterns have 
been identiﬁ  ed in embryonic chondrogenesis in vivo and 
progenitor cell diﬀ  erentiation  in vitro, enabling a 
mechanism to compare tissue engineered cartilage with 
natural development [11].
Mesenchymal cell diﬀ  erentiation into chondrocytes, and 
the associated regulation of extracellular matrix (ECM) 
deposition, is minutely co  ordinated by paracrine factors. 
TGF-β and bone morphogenetic protein (BMP) signal  ing, 
often through Sox9 as a transcriptional mediator, are 
responsible for initiating expression of carti  laginous ECM 
such as aggrecan, collagen types II and XI, ﬁ  bronectin 
and tenascin in in vitro murine micro  mass cultures 
[12,13]. Opposing roles for the involve  ment of the 
mitogen-activated protein kinase signal  ing components 
ERK-1 and p38 downstream of TGF-β superfamily stimu-
lation have been identiﬁ  ed during in vitro chondrogenesis 
[14]; suppres  sion of Erk-1/2 resulted in enhanced 
chondrogenesis whereas inhibition of p38 suppressed 
cartilage formation [15]. More speciﬁ  cally, inhibition of 
p38 signiﬁ   cantly repressed formation of pre-chondro-
genic nodules in vitro, sustained N-cadherin expression 
and increased expression of ﬁ   bronectin and α5β1 
integrin, while ERK inhibition showed no eﬀ  ect  on 
nodule formation, reduced expression of N-cadherin and 
accelerated reduc  tion of ﬁ  bronectin and α5β1 integrin 
expression during late stages of chondrogenesis [15]. Th  is 
delicate balance between signaling mechanisms is 
sustained in mature cartilage, ensuring maintenance of a 
healthy articular tissue [16].
Chondrogenic diﬀ   erentiation of adult human pro-
genitor cells in vitro through TGF-β1 is mediated intra-
cellularly by both Smad3 and Wnt-associated β-catenin 
[17]. By increasing nodule formation, Wnts 5a and 5b 
have been shown to promote early chondrogenesis in 
vitro  [18] and play an important role in chondrocyte 
diﬀ   er  entiation and proliferation in an in vivo mouse 
model by controlling expression of cell cycle regulators 
such as cyclin D1 and p130 [19]. However, expression of 
Wnts 14, 7a and 1 have been demonstrated to inhibit the 
chondrocyte maturation in in vivo chick models and in in 
vitro micromass cultures [20].
A distinct population of murine embryonic precursors 
located at the prospective joint will develop into adult 
articular cartilage and synovial tissues, in contrast to the 
remaining cartilaginous template that ossiﬁ  es to form the 
appendicular skeleton [21]. As the embryonic develop-
ment of articular cartilage proceeds from the preliminary 
cartilaginous template to an articulated joint with striated 
cartilage and underlying subchondral bone, Notch 
signaling plays a fundamental role as demonstrated in 
vivo with an avian model [22]. Notch signaling via JAG1 
is required to initiate chondrogenesis in adult human 
progenitor cells in vitro [23]; however, maintained Notch 
signaling in adult human progenitor cell micromass 
cultures suppresses diﬀ   erentiation by inhibiting Sox9 
binding of the collagen type II promoter [24], indicating 
that temporal regulation of Notch signaling is paramount 
to proper development.
Recent advances indicate a strong association between 
hypoxia-inducible factors (HIFs) in chondrogenesis and 
the development of OA. While HIF-1α stimulates 
chondrogenic diﬀ   erentiation, HIF-2α is involved in 
endo chondral  ossiﬁ   cation and cartilage degradation. 
Amarilio and colleagues [25] inactivated HIF-1α in 
mouse limb bud mesenchyme, resulting in abnormal 
joint and carti  lage formation in vivo, indicating HIF-1α 
regulates the diﬀ   erentiation of pre-chondrocytes. 
Further in vitro studies demonstrated reduced cartilage 
formation in HIF-1α-depleted micromass cultures and 
reduced ex  pres  sion of key chondrogenic markers Sox9, 
Sox6, aggrecan and collagen type II [25]. In vivo 
functional studies by Yang and colleagues [26] 
demonstrated that HIF-2α is a critical transcription 
factor that catabolically regulates cartilage degradation 
through matrix metallo  proteinase and ADAMTS (a 
disintegrin and metallo  proteinase with thrombospondin 
motifs) expression.
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above, as well as several other factors not reviewed here, 
results in the diﬀ   erentiation of an embryonic mesen-
chymal progenitor cell into a mature articular chondro-
cyte. Presumably chondroprogenitors residing in the 
adult have also been primed by these signals and will 
therefore respond similarly by undergoing chondrogenic 
diﬀ  erentiation when further stimulated, making them an 
attractive cell source for the regeneration of cartilage. 
Th  e successful identiﬁ  cation of a pool of chondropro-
genitors in vivo, followed by their isolation and in vitro 
expansion, is therefore a pre-requisite to their clinical 
application.
Progenitor cell tissue distribution
Adult progenitor cells have been described in vivo and in 
vitro as mobile cells with both diﬀ  erentiation and self-
renewal potential that reside in a niche adjacent to 
mature, diﬀ  erentiated cells [27]. Progenitors have been 
successfully retrieved from several sources, including 
adipose, synovium, synovial ﬂ   uid, perichondrium and 
bone marrow [28-31] (summarized in Table 1). Depend-
ing on the tissue source from which they are isolated, 
progenitors harbor distinct diﬀ  erentiation potential and 
occur at variable frequencies.
Eﬀ   orts by Friedenstein and colleagues [31] and 
Pittenger and colleagues [32] unequivocally demon  stra-
ted the presence and potential of bone marrow-derived 
mesenchymal stem cells (MSCs) with the innate ability to 
diﬀ  erentiate into multiple mesenchymal lineages in vitro. 
Despite their rare occurrence (0.001 to 0.01% of cells in 
the stromal compartment [32]), bone marrow-derived 
MSCs may be eﬃ   ciently isolated and expanded in culture 
without associated donor site morbidity.
Bone marrow-derived MSCs are isolated non-
selectively by exposing the mononuclear cell aspiration to 
tissue culture plastic. Adherent progenitors, termed 
colony forming unit-ﬁ   broblasts (CFU-Fs), initiate the 
generation of a clonal population of CD105-positive, 
CD73-positive, CD90-positive and CD44-positive cells 
that are then expanded in monolayer [33]. Clonal analysis 
of bone marrow-derived MSCs describes 20 to 50% of the 
total population of cells to be truly tri-potent, but most 
importantly has identiﬁ  ed a subpopulation of MSCs that 
retains only chondrogenic potential, or chondropro  geni-
tors [34]. As the resultant population of MSCs is hetero-
geneous, eﬀ  orts continue to identify and isolate a homo-
ge  nous chondroprogenitor cell population from marrow 
that would more eﬃ   ca  ciously repair diseased cartilage.
Similar to those in marrow, adult periosteal-derived 
multipotent progenitors are tri-potent [35]. Regardless of 
donor age, periosteal progenitors are clonogenic and 
have signiﬁ  cant in vitro expansion potential [36] with 
con  tinued positive expression of traditional bone 
marrow-derived progenitor cell markers such as CD105, 
CD166, CD13, CD73 and D7-FIB [28]. Most importantly, 
identiﬁ   cation of speciﬁ   cally chondro- and osteogenic 
precursors within the periosteum has been identiﬁ  ed, 
making this tissue an attractive tissue source for chondro-
progenitor isolation [37].
Th  e mature synovial membrane is composed of a 
ﬁ  brous external layer and an inner secretory layer that 
produces synovial ﬂ   uid. Synovial tissue-derived multi-
lineage progenitors may have the greatest overall thera-
peutic potential to regenerate damaged cartilage due to 
their impressive capacity for proliferation and their 
superior chondrogenic diﬀ   erentiation potential [38]. 
Interestingly, during the early stages of OA there is an 
increase in progenitor cell numbers in synovial ﬂ  uid, 
presumably as a result of synovial membrane degradation 
leading to their release into the synovial ﬂ  uid  [39]. 
Synovial membrane derived mesodermal progenitors 
uniquely are not depleted in number or potential with 
donor age [38], making them an attractive cell source for 
autologous therapy.
Like synovium and bone marrow, infrapatellar fat pad 
contains a readily abundant source of CD105-positive, 
CD44-positive and CD166-positive progenitor cells with 
the potential to diﬀ  erentiate into mesodermal lineages. 
CD271 expres  sion, a putative marker of the in vivo pro-
genitor cell [40], is highly expressed in adipose 
progenitors and is uniquely maintained with prolifera-
tion, indicating retention of their progenitor capacity 
upon expansion [29].
Although healthy mature cartilage is primarily com-
posed of mature chondrocytes, progenitor cells with 
chondro  genic capacity have been isolated from the 
super ﬁ  cial zone of articular cartilage [41]. Additionally, 
chondroprogenitors have been identiﬁ   ed in arthritic 
cartilage after their migration from the bone marrow 
through breaks in the tidemark and into the diseased 
cartilage [42]. With two potential sources of progenitor 
cells, one in the healthy superﬁ   cial zone and another 
generated as a repair response to disease, the develop-
ment of technologies to harness and retain their potential 
may oﬀ  er novel regenerative therapeutics.
Progenitor cells have also been identiﬁ  ed in tendon, 
speciﬁ  cally in an ECM-rich niche. Th  e tendon-derived 
stem/progenitor cells (TSPCs) are clonogenic with a 
higher rate of proliferation compared to bone marrow-
derived MSCs. TSPCs are multipotent with an enhanced 
potential for osteo- and adipogenic diﬀ  erentiation com-
pared to bone marrow-derived progenitors. With 
diminished chondrogenic potential and proﬁ  cient teno-
genic potential, TSPCs are perhaps best suited for tendon 
repair applications [43].
Comparison of progenitors derived from adult bone 
marrow, synovium, periosteum and adipose has 
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types [29,30]. Upon initial isolation of progenitor cells, 
there are signiﬁ  cantly fewer CFU-Fs in bone marrow-
derived cells compared to progenitors from adipose, 
periosteum or synovium. Synovial ﬂ   uid and bone 
marrow-derived pro  genitor cells share a similar chondro-
genic or osteo  genic potential [44]; however, synovial 
membrane-derived cells in particular retain signiﬁ  cant 
potential for chondrogenesis [38]. Together, these adult 
tissue sources oﬀ  er an opportunity to speciﬁ  cally isolate 
progenitors that when clonally analyzed are predisposed 
to diﬀ   er  en  tiate into chondro  cytes, thereby oﬀ  ering  a 
source of highly eﬃ   cacious repair cells. Figure 1 depicts 
some possible sources of chondroprogenitors. Th  e 
increased potential of synovium-derived progenitors may 
be associated with the proximity of the niche they reside 
in to articular cartilage. A common embryonic genesis 
for articular cartilage and synovial tissue may also be a 
factor [21]. Migration of progenitor-like cells from 
marrow to OA cartilage has been suggested but has not 
as yet been identiﬁ   ed in the healthy joint and the 
presence of marrow-derived mesenchymal-like progeni-
tors in rheumatoid arthritic pannus highlights an addi-
tional route for migration of marrow-derived chondro-
progeni  tors [45]. However, identiﬁ  cation of the optimal 
chondro  progenitor awaits a direct intra-donor compari-
son of cells isolated from the various sources.
Clinical considerations and therapeutic 
applications
Articular chondrocytes, when explanted and expanded in 
vitro, lose their chondrocytic phenotype as indicated by 
morphometric changes and elimination of collagen type 
II deposition [46]. Th  e  re-diﬀ  erentiation of these cells in 
vitro regenerates their articular phenotype while the 
diﬀ  erentiation of a progenitor cell in vitro results in the 
generation of a transient, pre-hypertrophic chondro  cyte, 
similar to the chondrocyte phenotype in the developing 
embryonic skeleton [47], highlighting the in  herent 
diﬀ  erence between progenitors and native chon  dro  cytes 
[48]. Essential to the functional formation of neocartilage 
through the implementation of progeni  tors is the 
acknowledgement of these evident diﬀ   erences in the 
phenotypic state, and our ability to develop methods to 
overcome the present gaps. It is crucial that research 
focuses on not only the signaling events that are known 
to support chondrogenic diﬀ  erentiation in the embryo 
but also on the molecular events that fail to initiate in 
progenitor cell diﬀ  erentiation.
Bone marrow-derived MSCs have been directly 
injected [49] or combined with a scaﬀ  old and implanted 
[50] into the intra-articular space in vivo in an eﬀ  ort to 
assess their potential for eﬃ   cacious repair of damaged 
cartilage tissue or diseased joints. Th  ese results have 
proven to be ambiguous and unsatisfactory as a result of 
low viability and retention of the cells [49]. Due to 
inconsistency in results and association with hypertrophy 
and ossiﬁ  cation, there are very few human clinical trials 
investigating heterogeneous bone marrow-derived MSCs 
as a therapeutic for cartilage repair.
Th  e ongoing Chondrogen clinical trial is currently 
investi  gating the application of bone marrow-derived 
MSCs to treat meniscal damage and thereby delay the 
onset of OA. Conducted by Osiris Th  erapeutics, 
Table 1. Overview of progenitor cell tissue sources
Source  Advantages  Disadvantages  Cell surface phenotype 
Bone marrow   Twenty to fi  fty percent of cells are tri-potent  Heterogeneous population of cells  CD105+, CD73+, CD44+, CD90+, 
[31-33,44]  Contains specifi  cally chondroprogenitor   Contains fewer CFU-Fs compared to other  CD271+, CD14+, CD13+, CD166+, 
 subpopulations  cell  sources  CD34-, CD45-, CD117-, CD31-, 
  High expansion potential  Invasive procedure to harvest  VEGFR-2- 
Synovium and   High expansion potential regardless of donor age  Heterogeneous population of cells  CD105+, CD73+, CD44+, CD90+, 
synovial fl  uid   Superior chondrogenic diff  erentiation potential    CD271+ , CD13+, CD166+, CD10-, 
[38,44]   No reduction in cell number or potential with     CD34-, CD45-, CD117-, CD31-, 
 donor  age    VEGFR-2-
  Increase in progenitor cell numbers in early OA   
Infrapatellar fat   Abundant source of progenitor cells  Comparable diff  erentiation capacity to other  CD105+, CD73+, CD44+, CD166+, 
pad [40,44]  Superior retention of diff  erentiation potential   tissue sources  CD271+, CD13+, CD90+, CD34-, 
  upon expansion  Relatively early senescence  CD45-, CD31-, VEGF-2-
Tendon [43]  Tri-potent cell population, positive chondrogenic   Low availability of autologous tendon tissue  CD105+, CD73+, CD44+, CD90+, 
 diff  erentiation, however, excelling in osteo- and   Minimal chondrogenic capacity  CD271+, CD13+, CD166+, CD14-, 
 adipogenic  potential    CD34-, CD45-, CD117-, CD31-, 
  Signifi  cant expansion potential    VEGFR-2-
Periosteum [28]  Progenitors are multi-potent  Consists of a heterogeneous population of  CD105+, CD166+, CD13+, CD73+, 
 Signifi   cant  in vitro expansion potential and   cells  D7-FIB+, CD90+, CD44+, CD10+, 
  clonogenicity despite donor age  Invasive harvest procedure  CD34-, CD45-, CD117-, CD31-, 
     VGFR-2-
Depending on the adult source tissue, isolated progenitor cells vary in cell surface phenotype, expansion and diff  erentiation potential. Before clinical application, 
careful consideration of the adult tissue source and capability of the derived reparative cell is therefore warranted. CFU-F, colony forming unit-fi  broblast; OA, 
osteoarthritis.
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clinically signi  ﬁ  cant improvement in pain experienced by 
patients post-injury with application of MSCs [51]. Th  e 
application of Chondrogen was well tolerated by recipi  ents 
and superior to currently available, comparable products 
on the market. With advances in chondropro  geni  tor cell 
isolation and culture techniques, products such as this will 
be improved upon by replacing large numbers of perhaps 
minimally eﬃ     cacious heterogeneous MSCs with low 
numbers of highly eﬃ   cacious chondroprogenitors.
To treat chondral defects, Advanced Technologies and 
Regenerative Medicine is currently investigating a 
cartilage autograft implantation system where autologous 
healthy cartilage is harvested from non-weight bearing 
regions, minced and re-distributed on a scaﬀ  old  for 
implantation. Initial results have been promising, 
supporting a phase III clinical investigation [52]. If left 
untreated, lesions such as these regularly result in the 
onset of OA. It is possible that the reparative cell 
responsible for the generation of neocartilage in this trial 
is indeed the re-implanted chondroprogenitor residing 
on the superﬁ  cial surface of the harvested cartilage tissue. 
By identifying the reparative cell in this application, a less 
invasive methodology for reparative cell isolation could 
be developed, thereby greatly reducing donor site 
morbidity as well as enhancing the eﬃ   cacy of the therapy.
TissueGene, Inc. is currently investigating the safety of 
intra-articular application of chondrocytes modiﬁ  ed 
virally to overexpress TGF-β1 as a potential treatment for 
arthritic lesions [53]. Although preliminary results are 
not yet available, re-creation of the embryonic environ-
ment by supplementing cells with TGF-β1 may signiﬁ  -
cantly contribute to cartilage repair over the application 
of chondrocytes alone, especially after their in vitro 
expansion and consequential de-diﬀ  erentiation.
Th  e beneﬁ   ts and disadvantages of allogeneic versus 
autologous cell-based clinical therapies continue to be 
debated. In a clinical study supported by the National 
Institutes of Health, this speciﬁ   c question will be 
addressed by comparing autologous and allogenic MSC 
therapies in the setting of heart failure [54]. Recent 
phase I clinical administration of allogenic MSC therapies 
to myocardial infarct patients validated the safety of 
allogenic cells [54] and autologous cells [55]. However, 
their long-term survival, engraftment and mechanism of 
action remain unclear [56].
Conclusion
Several million people worldwide suﬀ   er from OA, a 
chronic, debilitating disorder of the articulating joints. As 
current clinical interventions do not stimulate the 
genera  tion of a mechanically sound reparative tissue, but 
focus on the short-term relief of OA symptoms, the ﬁ  eld 
now looks to progenitor cell-based therapies as our 
future; speciﬁ  cally, progenitor cells primed for chondro-
genic diﬀ  erentiation. Chondroprogenitors residing in the 
adult have hypothetically been primed for chondrogenic 
diﬀ  erentiation with Wnts, FGFs and TGF-β superfamily 
members; just as embryonic limb mesenchyme is 
inﬂ  uenced, and, when stimulated, will diﬀ  erentiate into 
high quality articular cartilage. Recent chondrocyte- or 
MSC-based clinical trials have failed to meet their 
primary endpoints, often due to our minimal knowledge 
of their mechanism of action and fate following delivery. 
Nevertheless, the clinical application of chondroprogeni-
tors for cartilage regeneration may have a bright future 
with a greater understanding of their embryonic develop-
ment and the identiﬁ  cation of a reliable tissue source. Th  e 
clinical application of a homologous chondroprogenitor 
population will eliminate the need for heterogeneous cell 
therapies [56] and result in an eﬃ   cacious,  minimally 
invasive approach to articular cartilage repair.
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Figure 1. Potential sources for isolation of chondroprogenitors. 
Progenitor cells with chondrogenic potential have been isolated 
from bone marrow, synovium, perichondrium and cartilage itself. 
The relative ability of these cells to contribute to normal cartilage 
homeostasis or repair of diseased tissue may be related to their niche 
or developmental origin.
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